">VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 25, 2013) - Sirona Biochem Corp. (TSX VENTURE:SBM)(SRBCF)(ZSB.F) is pleased to announce the signing of a Letter of Intent (LOI) to create an extended collaboration with VitamFero. The goal of the collaboration is to apply Sirona Biochem's patented glycoprotein technology to the preservation of live attenuated animal vaccines.
"We are proud to be developing a partnership where our two unique technologies will be combined with the intent of advancing the science, economics and preservation capabilities of animal vaccines," said Neil Belenkie, CEO of Sirona Biochem.
"VitamFero is pleased to strengthen its partnership with Sirona Biochem. We are confident that strong synergies are to emerge from the extended collaboration that is going to be initiated," said Pascal Breton, CEO of VitamFero.
VitamFero develops live and attenuated animal vaccines against various infectious diseases, especially against Apicomplexa parasites. VitamFero intends to develop an effective protocol that, beyond their highly proven efficacy, extends the practicability of handling the anti-parasite vaccines. Further to the MTA signed in March 2013, VitamFero will evaluate Sirona Biochem's synthetic preservation technology to optimize its biopharmaceutical formulation and storage of its vaccine.
Using its proprietary chemistry technology, Sirona Biochem is developing biological preservation compounds to extend the life of stem cells, blood platelets, islets cells, tissues, organs and other biologics. By preserving these biologics, storage and transport times can be extended, such as in organ transplantation, thereby reducing or eliminating unnecessary disposal of valuable biological assets.
VitamFero is a privately owned biotech company whose mission, founded on an innovative and patented technology (i.e. Toxo KO and Neo KO), is to create, develop, register and market novel anti-infectious vaccines, first against Apicomplexa parasites such as Toxoplasma gondii (toxoplasmosis agent), Neospora caninum (neosporosis agent) and Cryptosporidium parvum (cryptosporidiosis agent). With headquarters in Evry - Genopole® (France) and laboratories in Tours (France), VitamFero is involved primarily in veterinary healthcare. For more information, visit: www.vitamfero.com.
About Sirona Biochem
Sirona Biochem is a biotechnology company developing diabetes therapeutics, skin depigmenting and anti-aging agents for cosmetic and pharmaceutical use, biological ingredients and cancer vaccine antigens. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. Sirona Biochem is the parent company of French-based biotechnology company TFChem. For more information visit: www.sironabiochem.com.
Sirona Biochem Corp also announces it has granted additional incentive stock options under its Stock Option Plan to directors and consultants exercisable for up to 700,000 shares of the Company. The options are exercisable on or before June 25, 2018 at an exercise price of $0.15 per share.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward- looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
- Stocks & Offerings
- Health Care Industry
Chief Financial Officer
Recommended for You
With Target already reeling from a massive hack that left up to 40 million credit and debit cards compromised, The New York Times now reports that all that data has been pouring into the black market since the break-in. Security experts, including security blogger Brian Krebs, say that criminals…The Verge
Your Money: Consumer watchdogs urge caution with deferred-interest-rate deals.USA TODAY
Jack Dorsey, CEO of Square, gives back $100 Million of Equity to Incentive Square Employees, But What About the Taxes?Forbes
As Mikhail Khodorkovsky ends more than a decade in prison, the man who built Russia’s largest oil company following the collapse of communism will find an industry where the state dominates once again....Bloomberg
A remarkable story of a U.S. Air Force general with unique knowledge of U.S. nuclear missiles being set up in Russia, with CNBC's Eamon Javers.CNBC Videos
Feel no remorse for insurers. They leapt into President Obama's arms salivating for 30 million new clients to service.The Wall Street Journal
Andrew Biggs of the American Enterprise Institute, whose disdainful take on the plight of older workers I described this week as "fatuous and flatly untrue," defended his position Thursday as ...Los Angeles Times
American Express Co (AXP) has agreed to let merchants charge extra for transactions paid with the company's credit and charge cards, in a legal settlement that its proponents said could change consumer spending habits. The settlement resolves two class actions filed by merchants that have been…Reuters
I am always 50 – 50 when it comes to filling out surveys for people. Lately, the surveys are so skewed, it is almost unethical. I was at one retail place and I finished making a big purchase. The person helping me pleaded with me to complete an email survey and make sure to mark...Business 2 Community
States are stepping up efforts to help consumers who find mysterious, and usually bogus, charges on their phone bills.USA TODAY
Walgreen Co. reported a jump in first quarter profit to $695 million from $413 million.The Wall Street Journal
Congress only has until late February or early March to vote to increase the federal debt ceiling, Treasury Secretary Jacob Lew said.MarketWatch
Target's data-security nightmare threatens to drive off holiday shoppers during the company's busiest time of year. The nation's second-largest discounter acknowledged Thursday that data connected to about ...Associated Press
In a further effort to placate consumers whose individual plans are being discontinued at the end of the year, last night the Obama administration sprung a surprise announcement that people in th...Consumer Reports
Mark Hannah, Democratic political analyst; Jim Pethokoukis, American Enterprise Institute; and Jennifer Stefano, Americans for Prosperity PA state director, discuss hardship exemptions under Obamacare.CNBC Videos
Miami has sued Bank of America , Wells Fargo and Citibank in U.S. federal court in Florida, for discriminatory mortgage lending practices against minority residents that resulted in a rash of foreclosures, the city said on Thursday. The lawsuits, filed on Dec. 13, accuse the banks of engaging in a…Reuters
Max Messmer, chairman of Accountemps, said Mondays can be productive because many workers spend the day catching up from the previous week and planning the one ahead. "The goal should be to maintain the positive momentum established on Tuesday throughout the week." To help make that happen,…LiveScience.com
As a deadline approaches, more people are trying to figure out the intricate cost-sharing arrangements of various options.The New York Times
Cramer has spotted signs in the market that he hasn't seen since the great bull market of the 1990s.CNBC
I dread going to the mall around the holidays. At least 10 minutes of circling before you can find a parking spot, crowded stores and insane lines by the cash registers. This year, I bought my gifts early ...StreetAuthority Network